RSS   Newsletter   Contact   Advertise with us
Post Online Media

Hugh Rosen joins Regulus board of directors

Hugh RosenRegulus Therapeutics Inc., a biopharmaceutical company, announced Hugh Rosen was elected to the company's board of directors.

Dr. Rosen is a Professor in the Departments of Chemical Physiology & Immunology at The Scripps Research Institute in La Jolla, California where he focuses on the study of lymphocyte trafficking and barrier regulation by signaling lipids, and contributing towards the development of translational infrastructure at TSRI.

Article continues below

READ MORE Regulus appoints Joseph P. Hagan COO

He also serves as Chairman of the Committee for Advance Human Therapeutics of TSRI.

Prior to joining The Scripps Research Institute, Dr. Rosen served in various capacities at Merck Research Laboratories, including Executive Director and Therapeutic Area head, and chair of Merck's Anti-bacterial and Anti-fungal Worldwide Business Strategy Team.

Dr. Rosen was the Scientific Founder of Receptos, Inc., now a wholly owned subsidiary of Celgene Corporation, and currently serves on its Scientific Advisory Board. He also serves on the Scientific Advisory Board of ActivX Biosciences Inc.

Dr. Rosen received his M.D. from University of Cape Town and his Ph.D. from University of Oxford.




What to read next



 LATEST MOVES FROM California 





More inside POST
 
 

We use cookies to ensure that we give you the best experience on our website. Please allow cookies for fully-functioning website.

Allow Cookies Privacy Policy